Moreover, in a tumor cell xenograft model, a significant reduction in tumor volume was observed after treatment with an EphB4 inhibitor, reinforcing its effectiveness as a new biomarker and molecular target for esophageal cancer (39). Here, EPHB4 is linked to neoplasm.